ArticleOncology letters2025
Hyalinizing trabecular tumor of the thyroid: A case report.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plasma cells and plasmacytoid features in thyroid lesions.Virchows Archiv : an international journal of pathology · 2026Review
- Case Report: Membranous/cytoplasmic Ki-67 staining and PAX8-GLIS3 fusion: defining the clinicopathological spectrum of hyalinizing trabecular tumor to optimize patient management.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A hyalinizing trabecular tumor (HTT), characterized by a trabecular growth pattern and notable hyalinization within the trabeculae, occurs at a rate of ~1%. As patients with HTT may be asymptomatic, accurate diagnosis is a challenge. Due to its resemblance to other tumors, such as papillary thyroid carcinoma and medullary thyroid carcinoma, a precise diagnosis necessitates both pathological and molecular examinations. Additionally, HTT is potentially malignant. The present study described the clinicopathological diagnosis of a patient with HTT; highlighting how an understanding of the clinical and pathological features of HTT is needed to provide an accurate differential diagnosis and thus tailor the treatment approach in order to effectively manage the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.